Assessment of the established medical science and practice of immunotherapy ch14.18 + GM-CSF + IL2 for highrisk neuroblastoma

This leads to the outcome of assessment that immunotherapy ch14.18 + GM-CSF + IL2 in cases of high-risk neuroblastoma is
still experimental and does not comply with the established medical science and medical practice criterion.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.